May 22, 2023 / 04:00AM GMT
Operator
Good morning, ladies and gentlemen. Welcome to the Q4 FY '23 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Mr. Utkarsh Gandhi, General Manager, Investor Relations for Glenmark Pharmaceuticals. Thank you, and over to you, sir.
Utkarsh Gandhi -
Thank you, Susan. Good morning, everyone, and welcome to the Q4 FY '23 Results Conference Call of Glenmark Pharmaceuticals Limited. Before we begin the Q&A, let's review the overall performance of the company for the quarter ended March 31, 2023.
For the fourth quarter of FY '23, Glenmark's consolidated revenue was at INR 33,737 million as against INR 30,191 million in the corresponding quarter last year, recording a Y-o-Y growth of 11.7%. For the 12 months of FY '23, Glenmark's consolidated revenue from operations was at INR 1,29,901 million as against INR 1,23,049 million, recording an overall growth of 5.6% on a Y-o-Y basis.
In terms of key highlights for the financial year FY '23.
Full Year 2023 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
May 22, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers